Canadian Drug Together with Magic Mushroom Effectively Treats Depression

According to a recent study, psychedelic mushrooms and new Canada drugs may lead to new manners of treating depression. 

"Psychedelics are thought of as 'mind-expanding' drugs, so it has commonly been assumed that they work by increasing brain activity, but surprisingly, we found that psilocybin actually caused activity to decrease in areas that have the densest connections with other areas," according to David Nutt, who's with the Department of Medicine at Imperial College London, was the senior author of both of the new studies. "These hubs constrain our experience of the world and keep it orderly. We now know that deactivating these regions leads to a state in which the world is experienced as strange." 

The impact of psilocybin reported by the study participants -- such as seeing "geometric" patterns, experiencing an altered sense of time and space, and unusual physical sensations -- correlated with a decreased flow of oxygen and blood to parts in the brain's posterior cingulate cortex and medial prefrontal cortex (mPFC), the study authors said. 

It's thought that the posterior cingulate cortex plays a role in consciousness and self-identity. Research has shown the medial prefrontal cortex to be especially active in people struggling with depression, so psilocybin's effect on this area of the brain could be responsible for some of the antidepressant effects reported in previous research, the study authors said. 

"Psilocybin was used extensively in psychotherapy in the 1950s, but the biological rationale for its use has not been properly investigated until now. Our findings support the idea that psilocybin facilitates access to personal memories and emotions," Dr. Robin Carhart-Harris, from the Department of Medicine at Imperial College London, and first author of both studies, said in the news release.  For the meantime, it is recommended to buy Celexa onlinefor the treatment of symptoms of patients with depression. 

"Previous studies have suggested that psilocybin can improve people's sense of emotional well-being and even reduce depression in people with anxiety. This is consistent with our finding that psilocybin decreases mPFC activity, as many effective depression treatments do. The effects need to be investigated further and ours was only a small study, but we are interested in exploring psilocybin's potential as a therapeutic tool," Carhart-Harris added.  With this, it is possible to design meds with this newly discovered remedy and have them available at various Canadian pharmacies. 

Depression is a state of low mood and aversion to activity that can affect a person's thoughts, behavior, feelings and physical well-being. Depressed people may feel sad, anxious, empty, hopeless, helpless, worthless, guilty, irritable, or restless. They may lose interest in activities that once were pleasurable; experience loss of appetite or overeating, have problems concentrating, remembering details, or making decisions; and may contemplate or attempt suicide. Insomnia, excessive sleeping, fatigue, loss of energy, or aches, pains or digestive problems that are resistant to treatment may be present. 

Depressed mood is not necessarily a psychiatric disorder. It is a normal reaction to certain life events, a symptom of some medical conditions, and a side effect of some medical treatments. Depressed mood is also a primary or associated feature of certain psychiatric syndromes such as clinical depression. 

A number of psychiatric syndromes feature depressed mood as a main symptom. The mood disorders are a group of disorders considered to be primary disturbances of mood. These include major depressive disorder (MDD), commonly called major depression or clinical depression, where a person has at least two weeks of depressed mood or a loss of interest or pleasure in nearly all activities; and dysthymia, a state of chronic depressed mood, the symptoms of which do not meet the severity of a major depressive episode. Another mood disorder, bipolar disorder, features one or more episodes of abnormally elevated energy levels, cognition and mood, but may also involve one or more depressive episodes.